1. HBW Insight
  2. >>Leadership

Next US FDA Commissioner Will Have Opening To Fill In Dietary Supplement Programs Office

 
• By Malcolm Spicer

Steven Tave on 15 March will move from ODSP director to lead ORA’s Office of Strategic Planning and Operational Policy. Agency’s next commissioner, who Capitol Hill lobbyists say could be named next week, will appoint a replacement.

Washington, D.C., USA- January 13, 2020: FDA Sign outside their headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.

The next US Food and Drug Administration commissioner will appoint the agency’s next dietary supplement programs chief as Steven Tave, the director since the programs were elevated from a division to an office in 2016, is moving to a regulatory affairs post.

With his move to the Office of Regulatory Affairs, Tave will join the FDA unit that conducts inspections of firms...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

People On The Move: Appointments At Opella, Stada, Futura

 
• By Tom Gallen

Latest European appointments: Opella names Germany director; Stada has new Western Europe head; Futura makes CEO change.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, home of HBW Insight, to focus on AI, business harmonization and long-term growth.

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

Health and Human Services secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

More from HBW Insight

Gardenia Blue, OrangeOvation, StellarYellow Latest Natural Pivots In US Food Color Market

 
• By Malcolm Spicer

FDA’s fourth approval in past two months for color derived from natural sources to use in foods is Gardenia Blue Interest Group’s color additive petition for gardenia blue. Lycored launches StellarYellow and C Clear as alternatives for synthetic dyes yellow Nos. 5 and 6 and OrangeOvation C Clear for

Stada Acquires Fortacell To Grow In Balkans

 
• By Tom Gallen

Stada's Serbian subsidiary Hemofarm has enhanced its offering in the dietary supplements category with the acquisition of Fortacell from Goodwill Pharma.

House Health Subcommittee Members Agree OMUFA Crucial, Split On FDA Staff Cuts’ Impact

 
• By Malcolm Spicer

Subcommittee members aren’t on same page about whether FDA staff cuts ordered by the Trump administration will prevent the agency from fulfilling its responsibilities for the OTC drug sector.